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Cast nephropathy is the most common cause of renal disease
in multiple myeloma, however, treatment with plasma
exchange remains controversial even after 3 randomized
controlled studies. We sought to determine the importance
of diagnostic confirmation and goal directed therapy in the
treatment of cast nephropathy in forty patients with
confirmed multiple myeloma and renal failure who
underwent plasma exchange. A positive renal response was
defined as a decrease by half in the presenting serum
creatinine and dialysis independence. No baseline differences
were noted between eventual renal responders and
non-responders. Three quarters of the patients with biopsy
proven cast nephropathy resolved their renal disease when
the free light chains present in the serum were reduced by
half or more but there was no significant response when the
reduction was less. The median time to a response was about
2 months. In patients without cast nephropathy, renal
recovery occurred despite reductions in free light chain levels
of the serum. No association was found between free light
chains in the serum, urinary monoclonal proteins, overall
proteinuria and cast nephropathy. We found that the
relationship between renal recovery and free light chain
reduction was present only in patients with biopsy proven
cast nephropathy showing the importance of extracorporeal
light chain removal in this disease.
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Renal failure is a common and serious sequela of multiple
myeloma. Reported incidence ranges from 18 to 56%
depending on definition.1–4 If not reversed, renal failure can
extol a significant impact on survival.2,5,6 Although presenta-
tion may be similar, the etiology is heterogenous. The most
common cause is light chain cast nephropathy (CN) seen in
B30% of the patients.7,8 Other more common etiologies
include immunoglobulin light-chain amyloidosis (AL) and
monoclonal immunoglobulin deposition disease. AL and the
rarer heavy-chain amyloidosis account for 5–11% of the
cases, whereas monoclonal immunoglobulin deposition
disease occurs at roughly half that frequency.8,9 Subtypes of
monoclonal immunoglobulin deposition disease include
light-chain deposition disease (LCDD), light heavy-chain
deposition disease, and heavy-chain deposition disease.10,11
Acute tubular necrosis (ATN) is common since nephrotoxi-
city from non-steroidal anti-inflammatory drugs and
iodinated contrast is enhanced in myeloma patients.9 Less
frequent renal manifestations include cryoglobulinemia,
proliferative glomerulonephritis, crystalline nephropathy,
and so on.12–17 More than one histological pattern can exist
in the same kidney. The most common combinations are CN
with ATN and CN with monoclonal immunoglobulin
deposition disease.8,9,18
The treatment of CN is controversial. To date, three
randomized controlled trials have evaluated the effectiveness
of plasma exchange (PLEX). Zucchelli et al.19 randomized 29
patients with serum creatinine (Scr) 45 mg per 100 ml to
receive hemodialysis and PLEX vs peritoneal dialysis. Eleven
patients from each group required dialysis. Renal function
improved in 13/15 treated with PLEX vs only 2/14 with
peritoneal dialysis. Unfortunately, five patients in the latter
group died within the first 2 months, and this was often cited
as a major weakness of the study. Johnson et al.20 reported on
21 patients, 12 of whom were on dialysis. Eleven patients
were randomized to receive PLEX. They noted no differences
in the overall renal recovery rate (control 50% vs PLEX 64%,
P¼NS); however, in a subgroup analysis of the dialysis
patients, renal recovery occurred only in those who received
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PLEX. The third and largest study published by Clark et al.21
involved 97 patients. Fourteen of the 39 control patients and
15/58 PLEX patients were on dialysis at baseline. In this
study, 69% of the control group and 58% of the PLEX group
reached a composite outcome, which included death, dialysis
dependence, or an estimated glomerular filtration rate
(eGFR) o30 ml min1 1.73 m2 at 6 months. The difference
was not statistically significant (P¼ 0.36) and PLEX was felt
to be ineffective.
Although Clark’s study was the largest of the three trials, it
also had the most serious limitations. First, despite being the
largest, the number of patients in Clark’s study was still small
and was at risk for beta error. This was further compromised
by the use of a composite outcome which disadvantaged
PLEX because patient who died with improved renal function
and those with eGFR o30 ml min1 1.73 m2 were consid-
ered failures. The most serious limitation however was that
the renal pathology was not verified due to the low biopsy
rate. Finally, no method was employed to assess the adequacy
of treatment. Thus, the efficacy of PLEX in the treatment of
cast nephropathy remains unsettled. Given the importance of
renal recovery in these patients, we performed this
retrospective study to investigate the effectiveness of PLEX
in the treatment of CN, when the diagnosis is confirmed by
renal biopsy and the treatment is guided by serum-free,
light-chain levels.
RESULTS
Forty patients met the inclusion criteria. Myeloma was newly
diagnosed in 67.5%. Median age was 67 (range 35–84 years)
with 60% male. Light chains were 45% k, 55% l. Eighteen
patients had monoclonal light chains without an intact
immunoglobulin (Figure 1). Baseline serum free light chain
(sFLC) was only available for 77.5%, since the FreeliteTM assay
was not commercially available until late 2001, and was not
used in our institution until late 2002–early 2003 (Figure 2a).
On the other hand, baseline serum M-protein was measured
in 97.5%. Serum FLC levels ranged from 3.3 to 8080 mg per
100 ml (normal values for k¼ 0.33–1.94 mg per 100 ml,
l¼ 0.57–2.63 mg per 100 ml). The lowest sFLC level from a
biopsy proven CN was 157 mg per 100 ml. The highest sFLC
level belonged to a patient with pure LCDD. Median
proteinuria was 3.1 g day1 (0.6–17.5 g day1) and urine
M-spike was 1.7 g day1 (0.01–15.3 g day1).
Median presenting Scr was 4.8 mg per 100 ml (2.0–18.6 mg
per 100 ml) corresponding to an eGFR of 11.0 (3–34)
ml min11.73 m-2. A historical Scr was available for 67.5%,
but only 10 were within 45 days of presentation. Nine
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Figure 1 | The distribution of monoclonal proteins amongst
patients with multiple myeloma and renal failure.
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
0 0
5
10
15
20
5
10
15
No  
biopsy
Cast 
nephropathy
Other 
pathology
No  
biopsy
Cast 
nephropathy
Other 
pathology
No  
biopsy
Cast 
nephropathy
Other 
pathology
SF
LC
 (m
g p
er 
10
0 m
l)
Ur
in
e 
M
-s
pi
ke
 (g
 da
y–
1 )
Pr
ot
ei
nu
ria
 (g
 da
y–
1 )
Figure 2 | Distribution of SFLC, urine M-spike and proteinuria in relation to renal pathology. (a) Serum FLC levels were similar amongst
patients with no biopsy 369 mg per 100 ml (3–1560), cast nephropathy 467 mg per 100 ml (157–6960), and other renal pathology 711 mg per
100 ml (106–8080); P¼ 0.40. (b) No significant difference was found in the urine M-spike for patients with no kidney biopsy 3.5 g day1
(0.1–8.1), cast nephropathy 1.7 g day1 (o0.1–15.3), and other pathology 1.1 g day1 (o0.1–4.9); P¼ 0.25. (c) Median proteinuria for patients
with no kidney biopsy was 4.6 g day1 (0.6–10.7), 2.6 g day1 (1.0–17.5) in cast nephropathy, and 2.3 g day1 (0.9–9.4) in other pathology.
No significant difference was noted; P¼ 0.55.
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patients (22.5%) required dialysis at presentation. Another
initiated dialysis while receiving PLEX and 3 others with Scr
of 3.0, 5.9 and 8.8 mg per 100 ml became dialysis dependent
much later. Two patients who presented with Scr of 18.8 and
4.3 mg per 100 ml became dialysis independent. Eleven
patients were dialysis dependent at the time of the study.
Eight patients had exposure to nephrotoxins: 5 non-steroidal
anti-inflammatory drugs, 2 intravenous contrast and 1
zoledronic acid. Other comorbidities included hypercalcemia
(2), plasma cell leukemia (2), large gastrointestinal bleeding
(1), and fever (2).
Twenty-eight (70%) patients underwent renal biopsy
without any serious complications. Pure CN was identified
in 18 (64.3%), with five patients having tubulointerstitial
infiltrates, of which two were chronic (Table 1). Neither
initial sFLC level (P¼ 0.38), serum M-protein (P¼ 0.89),
nor urine M-protein (P¼ 0.18), were predictive of CN.
Other renal pathologies included CN with LCDD (2), ATN
(3), LCDD (3), diabetic nephropathy with ATN (1), and
AL amyloidosis (1). Two other patients who did not have a
renal biopsy had amyloid identified on fat aspirate (1) and
bone marrow (1). In patients with CN, the median presenting
Scr was 4.8 mg per 100 ml (2.0–18.6 mg per 100 ml), vs 5.5 mg
per 100 ml (3.1–11.4 mg per 100 ml) in other renal
pathology and 4.2 mg per 100 ml (2.1–9.3 mg per 100 ml) in
those without a renal biopsy (P¼ 0.72). Thirty-one
patients had sFLC measured prior to PLEX. Median initial
sFLC level of CN patients was 466.5 (157–6960 mg per
100 ml), vs 711 (106–8080 mg per 100 ml) in other renal
pathology and 369 (3.3–1560 mg per 100 ml) in those with no
renal biopsy, P¼ 0.40. Urine protein and M-spike were
measured in 85% of patients. No differences were noted in
the urine M-spike or proteinuria among the three groups
(Figure 2b and c).
Overall, 18 of 40 (45%) patients achieved a renal response
after PLEX. No differences in age (68 vs 64 years, P¼ 0.1) or
sex (50% males vs 72.2% males, P¼ 0.15) were noted
between non-responders and responders respectively. The
baseline Scr (4.8 vs 4.8 mg per 100 ml, P¼ 0.47) and eGFR
(11.0 vs 11.5 ml min11.73 m2, P¼ 0.69) were also similar
between responders and non-responders respectively. Renal
response was similar between patients with a historical Scr
(P¼ 0.44), renal biopsy (P¼ 0.68), pre and posttreatment
sFLC measurements (P¼ 0.71), and those without. Median
Scr of responders was 3.0 mg/dl (1.6–7.0 mg/dl) after PLEX
and improved to 1.4 mg/dl (0.8–2.7 mg per 100 ml) at their
best. This represented an eGFR of 44.5 (26–102)
ml min11.73 m2. The median time to renal response was
61 days (3–170). In contrast, the non-responders had a
significantly higher posttreatment Scr (4.4 mg per 100 ml
(2.2 mg per 100 ml to dialysis), Po0.001) and lower eGFR
(12.5 ml min11.73 m2 (dialysis to 26 ml min11.73 m2),
Po0.001). Half of the non-responders became dialysis
dependent. No patient with LCDD responded but 1 of 2
patients with CN and LCDD did. Two of the nine patients
who presented on dialysis recovered their renal function.
Renal response also occurred in 4 patients who did not have
pure CN, (2) ATN, (1) AL amyloidosis, and (1) CN with
LCDD.
Twenty-eight patients had sFLC measured before and after
PLEX, 22 of whom also had a renal biopsy (Table 2). Renal
response was noted in 14 patients (50%). Serum FLC was
reduced by 450% in 11 of 14 renal responders, but in only
6 of 14 non-responders (P¼ 0.05; Figure 3). Renal response
occurred without 50% sFLC reduction in three patients
(1 AL, 1 ATN, and 1 was not biopsied). Their posttreatment
sFLC were between 215–1120 mg per 100 ml. On the other
hand, 6 patients (3 LCDD, 1 diabetic nephropathy, 1 CN with
an interstitial nephritis, and fibrosis and 1 CN precipitated by
intravenous contrast and had been on dialysis for 1 month
prior to diagnosis) had 450% sFLC reduction, but did not
achieve renal response.
The effect of sFLC reduction on renal response was most
important in the CN patients. In the 14 of 18 patients with
CN who had sFLC measured before and after PLEX, renal
response occurred in 77.8% (7/9) whose sFLC was reduced by
50% or more. One patient with chronic changes on the renal
biopsy and one whose renal failure was precipitated by
intravenous contrast did not respond. None of the five
patients witho50% reduction in sFLC had a renal response.
This difference in renal response between patients with
450% and o50% sFLC reduction was highly significant
(P¼ 0.005). Two patients whose sFLC reduction could not be
assessed also had a renal response.
Renal response was dependent on posttreatment sFLC
levels only in the patients with CN. The median posttreat-
ment sFLC of all responders was 131 mg per 100 ml
(72–1120 mg per 100 ml) vs 262 mg per 100 ml (30–4780 mg
per 100 ml) in all non-responders, P¼ 0.10. However, when
CN patients were analyzed separately, posttreatment sFLC
was significantly higher in the non-responders (272.5 mg per
100 ml (86–1020 mg per 100 ml) compared with responders
92.6 (79.2–143 mg per 100 ml), P¼ 0.03). This difference
between responders and non-responders was not seen in
patients with other pathology (312 vs 50.6 mg per 100 ml
respectively, P¼ 0.40) or patients without a renal biopsy (218
vs 390.5 mg per 100 ml, respectively, P¼ 0.99). In a logistic
regression model that adjusted for age, sex, and CN, renal
Table 1 | Renal pathology in renal responders and
non-responders
Renal pathology Non-responders Renal responders
Cast nephropathy 6 7
CN+tubulointerstitial nephritis 1 2
CN+chronic interstitial nephritis 2 0
CN+LCDD 1 1
LCDD 3 0
AL amyloidosis 0 1
ATN 2 2
CN, cast nephropathy; AL, immunoglobulin light-chain associated amyloidosis; ATN,
acute tubular necrosis; LCDD, light-chain deposition disease.
No patient with pure LCDD responded and only 2 of 4 patients with ATN responded
after PLEX.
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response was predicted by either posttreatment sFLC level
(P¼ 0.02) or 450% reduction of sFLC (P¼ 0.02).
The average number of PLEX performed was 6 (1–19).
This was higher for patients with CN than those with other
renal pathology (7.5 (2–19) vs 5.5 (2–7), respectively,
P¼ 0.01). Patients without renal biopsy had 6.5 (1–12)
exchanges similar to patients with CN (P¼ 0.64). The
number of PLEX did not differ significantly between renal
responders and non-responders (5.5 (1–12) vs 6.5 (2–19)
respectively, P¼ 0.28). No relationship was found between
the number of PLEX and the posttreatment sFLC levels
(P¼ 0.9).
Comorbidities appeared to have an impact on renal
recovery. No patients with plasma-cell leukemia achieved
renal response but both patients with hypercalcemia did.
Unfortunately, the percentage of sFLC reduction could not be
determined for these four patients. In five patients who took
non-steroidal anti-inflammatory drugs, only the two with
450% sFLC reduction achieved renal response. Both patients
with fever and one with gastrointestinal hemorrhage achieved
renal response, but sFLC was reduced by 450% in only one
of the fevers. None of the patients who developed renal
failure as a result of intravenous contrast (2) or zoledronic
acid (1) recovered their renal function despite 450% sFLC
reduction in one of contrast patients. Comorbidity as a whole
did not differ between renal responders and non-responders
(38.9 vs 40.9%, P¼ 0.90). However, patients who had either
plasma-cell leukemia, contrast, or zoledronic acid were less
likely to achieve renal response (P¼ 0.01). Despite that, these
factors were not found to be independent predictors of renal
response in the multivariate analysis.
Chemotherapy was used during PLEX in 85% of the
patients. The most common chemotherapeutic regimen was
high-dose dexamethasone. Renal response rate was 45% in
those treated with high-dose dexamethasone and PLEX. In
those with 450% reduction in sFLC, renal response rate was
71.4 vs 20% for those who did not (P¼ 0.1). The effect of
different chemotherapy regimen on renal response could not
be determined due to the small numbers. Survival was
significantly longer in patients who achieved renal response.
Median survival was 31.8 months for renal responders vs 11.0
months for non-responders (Figure 4). When survival was
analyzed for the impact of newly diagnosed vs relapsed
myeloma, significantly differences were noted (P¼ 0.0002).
This difference remained significant in a multivariate analysis
Table 2 | Characteristics and responses of patients with renal
biopsy
Other
pathology
Cast
nephropathy P-value
N 10 18
Age 69 (56–78) 65.5 (35–81) 0.29
Male 80% 44.4% 0.06
Initial Scr (mg per 100 ml) 5.5 (3.1–11.4) 4.8 (2–18.6) 0.73
Best Scr 4.3 (0.8–dialysis) 2.3 (1.2–dialysis) 0.33
Initial
eGFR (ml min1 1.73 m2)
10 (5–21) 11.5 (3–34) 0.55
Best eGFR 15 (5–102) 24.5 (5–54) 0.80
Renal biopsy results
Cast nephropathy 0% 100%
ATN 30%
CN+LCDD 20%
LCDD 30%
AL 10%
Diabetic nephropathy 10%
Chemotherapy 0.18
Dex/steroids alone 60% 50%
Melphalan and steroids 10% 5.6%
Thalidomide Dex 10% 16.7%
Bortezomib and Dex 0% 5.6%
VAD 0% 5.6%
MPT 10% 0%
Alemtuzumab 0% 5.6%
Cyclophosphamide 0% 11.1%
None 10% 0%
Outcome
Renal response 30% 50% 0.30
Dialysis at baseline 20% 27.8% 0.64
At 6 months 40% 22.2% 0.32
Mortality at 6 months 20% 22% 0.89
sFLC response to PLEX
N 8 14
sFLC (mg per 100 ml)
Initial 711 (106–8080) 466.5 (157–6960) 0.40
After PLEX 211 (30–4780) 143 (79–1020) 0.16
50% sFLC reduction 75% 64.3% 0.60
AL, light-chain amyloidosis; ATN, acute tubular necrosis; CN, cast nephropathy; DEX,
dexamethasone; eGFR, estimated glomerular filtration rate; LCDD, light-chain
deposition disease; MPT, melphalan, prednisone, and thalidomide; Scr, serum
creatinine; sFLC, serum free light chain; VAD, vincristine, adriamycin, and
dexamethasone.
Best Scr and eGFR were obtained from the best Scr after PLEX treatment.
Data on free light chain response to plasma exchange were collected on 22 of 28
patients. The rest of the data reflect all 28 patients with a renal biopsy.
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Figure 3 | Renal response by reduction of sFLCs. Of the six
patients with 450% reduction in sFLC without renal response,
3 had LCDD, 1 had diabetic nephropathy with acute tubular
necrosis, 1 had cast nephropathy precipitated by intravenous
contrast, and 1 had cast nephropathy with atypical
tubulointerstitial nephritis and fibrosis. Three patients had o50%
reduction in sFLC and renal response. One had AL amyloidosis,
1 had ATN, and 1 was not biopsied.
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(P¼ 0.004) and was found to be even more important than
renal response (P¼ 0.07).
DISCUSSION
Plasma exchange was first used in the treatment of acute
renal failure associated with multiple myeloma in 1976.22
Since then, dozens of case reports and two randomized trials
have documented its efficacy.19,20 This led to a consensus
statement by the Scientific Advisors of the International
Myeloma Foundation formally endorsing its use.23 Less than
3 years later, the results of a multicenter trial from Canada
challenged the effectiveness of PLEX and the consensus
statement.21 As a result, the American Society for Apheresis
downgraded the use of PLEX in renal failure associated with
multiple myeloma from a Category II indication (accepted as
a supportive or adjunct therapy) to a Category III indication
(suggestion of benefit for which existing evidence is
insufficient or conflicting to establish the efficacy or clarify
the risk/benefit).24 The exact impact on the treatment of
these patients is unknown, but given that reimbursement for
PLEX can now be tested, it is likely to be significant. Given
the importance of this issue, it is imperative to understand
the study that resulted in this change in practice, especially
since questions have been raised about its methodology.25
The randomized controlled trial by Clark et al.21 was
the third and largest randomized controlled trial looking at
the effect of PLEX on myeloma associated renal failure.
Despite its randomized controlled design, several serious
limitations can potentially alter its outcomes and conclu-
sions. First of all, in a small study with negative results, it is
often difficult to determine whether the negative results were
due to ineffectual therapy or an underpowered study. The
power was further compromised by the use of a composite
outcome, which considered death of any cause and eGFR
o30 ml min1 1.73 m2 a failure. The significance of
30 ml min11.73 m2 in the composite outcome is unclear.
While the effect of dialysis dependence on survival has been
demonstrated, there is no evidence to suggest that an eGFR of
o30 ml min1 1.73 m2 is associated with poorer prognosis
in myeloma patients.1,2,5,19 And while an eGFR of
o30 ml min1 1.73 m2 is certainly clinically significant, it
still represents a tremendous improvement in the quality of
life over dialysis. Dialysis dependence also limits the most
advanced therapies because of protocols and/or bias and may
contribute to the poorer survival. However, the most serious
limitations of the study had to be the lack of renal disease
confirmation and a therapeutic marker. The deficiency in
renal biopsies and the lack of a therapeutic marker made it
impossible to determine the disease being treated and the
adequacy of treatment. Despite the multicenter, randomized
controlled design, these limitations seriously undermined
their results and conclusions.
In this study, PLEX was found to be effective at reversing
renal failure if it was due to CN and if sFLC levels can be
reduced by at least 50%. When both criteria were met, renal
function improved in 78% of the patients. The renal function
did not improve in any CN patient whose sFLC could not be
reduced by 50%. This relationship was only significant in
patients with CN. In patients with other renal pathology, the
recovery of renal function did not depend on sFLC reduction.
Improvement in renal function was seen despite o50%
reduction of sFLC, whereas 450% reduction did not insure
renal recovery. This finding may explain the differences in
outcomes reported by the three randomized trials especially
in the latest study where biopsy was rarely performed and no
marker of therapy was used.19–21
The result of this study showed that confirmation of the
diagnosis was a key factor in the success of therapy. While
reduction of free light chains was important, only patients
with CN responded to PLEX in a predictable manner. Renal
biopsy was necessary in order to confirm the diagnosis. No
association was found between CN and sFLC levels although
no CN was seen in patients with sFLC o157 mg per 100 ml.
Urine protein and M-spike were even less helpful having
neither positive nor negative predictive values. Our data are
consistent with previous studies in which 41/3 of our
patients biopsied did not have CN.9,10,15 This reinforces our
belief that any study that does not confirm the diagnosis with
renal biopsy should be interpreted with caution. Histological
features may also be helpful in prognostication as patients
with CN and chronic tubulointerstitial changes did not
respond to treatment. This is consistent with previous
observations.6 Renal biopsy was safe in our population. The
concern that renal biopsy is risky in this population appears
unsupported.
In this study, PLEX did not reduce sFLC in an expected
manor. Thus, studies that arbitrarily assign the number of
treatments in advance may be under-treating some patients.
Instead, PLEX should be guided by sFLC levels to avoid
under- and over-treatment. In addition, the variable reduc-
tion of sFLC by PLEX highlights the importance of
chemotherapy. Refractoriness to PLEX most likely reflects
the high rate of light-chain production and myeloma activity.
In this situation, effective chemotherapy can significantly
slow the production light chains, whereas PLEX can enhance
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Figure 4 | Patient survival based on renal response. Median
survival for renal responders was 31.8 months vs 11.0 months in
non-responders; P¼ 0.03.
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its removal, which is impaired by the renal failure. One could
argue that with effective chemotherapy PLEX may be
unnecessary. However, response to PLEX was noted in
patients who did not receive chemotherapy. In addition,
response to any particular chemotherapy regimen cannot be
predicted and may be delayed. PLEX can provide a bridge
until an effective chemotherapy can be delivered or take
effect. This is important since chronicity of renal failure can
affect the degree of recovery.
There were several limitations we would like to point out
in our study. First, as a retrospective study the treatments
received were not controlled. Neither the chemotherapy nor
PLEX was uniformly applied. In those who were found not to
have CN, PLEX was discontinued without regard to sFLC
level. This opens the argument that non-CN patients may
require a different level of sFLC reduction in order achieve
renal response. While this is certainly possible, the non-
responders without CN actually had the lowest posttreatment
sFLC level (50.6 mg per 100 ml), which was far below the
median (312 mg per 100 ml) attained by the responders in
that group. Another limitation is the differences between our
patients and those of the previous randomized trials. More
patients from Zucchelli’s study and Johnson’s study were
dialysis dependent (82.8 and 57.1%, respectively) than the
ones from this study (22.5%) and in Clark’s study
(29.9%).19–21 However, pathologically our patients were more
similar to the patients in Johnson’s and Zucchelli’s study,
whose renal diagnosis was confirmed by renal biopsy in 76
and 59%, respectively. This could not be determined for
patients in the Clark’s study, since they were rarely biopsied.
And unlike Clark’s study, which required a baseline Scr
within 30 days of the study, the duration of renal failure
could not be determined for 32.5% of our patients.
Fortunately, presence of a historical Scr did not affect renal
response. Finally, this small retrospective study limits the
strength of the evidence.
In conclusion, our study suggests that PLEX may still be
beneficial in the treatment of cast nephropathy. We agree that
PLEX has no role in the treatment of undifferentiated renal
failure in patients with multiple myeloma.21 However, our
small study suggests that when cast nephropathy can be
confirmed, renal recovery seems to be highly associated with
significant sFLC reduction. This relationship was recently
reported by others using a large pore dialyzer to remove
pathologic light chains from patients with cast nephro-
pathy.26 The large-pore dialyzer is currently not available in
the United States, but it supports our observation that more
rapid sFLC reduction is beneficial in cast nephropathy. This
relationship definitely deserves further studies, as sFLC may
provide the key target for therapy in cast nephropathy. Future
study design should incorporate three elements, (1) tissue
confirmation of cast nephropathy, (2) a set target for the
sFLC reduction instead a preset number of plasma exchanges,
and (3) a single highly effective chemotherapeutic regimen.
Patients should be hydrated while waiting for biopsy results
to rule out pre-renal causes. These elements would insure
diagnosis and therapeutic equivalency, thus isolating PLEX as
the independent variable. Although still preliminary, the
results of this study and others give a new enthusiasm that
extracorporeal removal of light chains may be beneficial in
the treatment of cast nephropathy. Validation may come yet
for plasma exchange after over three decades.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board at the
Mayo Foundation, in accordance with the Declaration of Helsinki
Principles and the Health Insurance Portability and Accountability
Act (HIPPA) guidelines. The Transfusion Medicine Therapeutic
Apheresis Unit records were examined for patients with a diagnosis
of multiple myeloma who underwent plasma exchange between
January 2002 and June 2006. The number of plasma exchanges,
laboratory values, demographic data, and additional treatments
were extracted from our electronic databases.
sFLC was measured by nephelometry using the BN II
nephelometer (Dade Behring, Deerfield, IL, USA) and Freelite
Serum Free Light Chain Assays (The Binding Site Inc., San Diego,
CA). The internal coefficient of variance for k-light chain was 7.9%
at 0.05 mg per 100 ml and 7.9% at 34 mg per 100 ml. For l-light
chain, the coefficient of variance was 10% at 0.05 mg per 100 ml and
2.6% at 43 mg per 100 ml. Total protein and urine monoclonal (M)
spike were obtained from urine protein electrophoresis. Renal
biopsies were obtained under real time ultrasound guidance and
were processed for light microscopy, immunofluorescence and
electron microscopy. Congo red staining was performed based on
the history, histological features, or at the request of the physician.
PLEX was performed with the COBE Spectra (Gambro BCT,
Lakewood, CO, USA) running version 7 software. One plasma
volume exchange was performed daily to every other day. Sodium
citrate was used as the anticoagulant and the plasma volume was
replaced with 5% albumin. Fresh frozen plasma was used if an
invasive procedure was planned. PLEX was usually performed via
central vascular access. Initially, patients usually received five
exchanges unless complications prevented further treatment. Later,
exchanges continued until sFLC was below 200 mg per 100 ml. PLEX
was deemed ineffective and was discontinued if the sFLC level could not
be altered after five exchanges. Dialysis was performed based on the usual
criteria. Renal biopsy was obtained at the discretion of the nephrologist.
The choice of chemotherapy was determined by the hematologist.
Multiple myeloma was defined by lytic bone lesions or bone
marrow plasmacytosis 410%. Renal failure was defined as a Scr
50% above the baseline or X2.0 mg per 100 ml if baseline is
unavailable. eGFR rate was calculated using the Modification of Diet
in Renal Disease Study (MDRD) equation.27 Patients who were
dialysis dependent were assigned an eGFR of 0. Exposure to non-
steroidal anti-inflammatory drugs and other nephrotoxins was
recorded. In this study, renal response was defined as a 50%
reduction of presenting Scr and dialysis independence at 180 days.
Statistical analysis was performed using JMP version 6.0.0 (SAS
Institute Inc., Cary, NC, USA). Pearson’s w2-tests were performed on
categorical data. Two-sample t-tests and Wilcoxon rank-sum tests
were used to compare continuous variables between groups. A
logistic regression model with age, sex, renal biopsy results,
presenting Scr, initial sFLC, posttreatment sFLC, number of plasma
exchanges, and chemotherapy was used to identify an association
with renal response. Survival was analyzed using the Kaplan–Meier
method.
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